Results 131 to 140 of about 2,668,334 (282)

Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction. [PDF]

J Biomed Sci
Chung DJ, Chen SP, Liu WH, Liu CY, Su NW, Hsu C, Tsai HY, Yang KC, Wu CK, Lin SW, Shie JJ, Zhao MT, Wei TT.   +12 more
europepmc   +1 more source

GPR55 – a putative “type 3” cannabinoid receptor in inflammation

Journal of Basic and Clinical Physiology and Pharmacology, 2016
Hyewon Yang, Juan Zhou, C. Lehmann
semanticscholar   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, Volume 65, Issue 4, Page 706-723, April 2026.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Identification of the cannabinoid receptor 1 antagonist, ibipinabant, as a potent inhibitor of <i>Neisseria gonorrhoeae</i>. [PDF]

Antimicrob Agents Chemother
Dove AS, Abdelsattar AS, Abutaleb NS, Seleem MN.   +3 more
europepmc   +1 more source

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

FEBS Letters, 1994
M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, Christian Congy, Serge Martinez, J. Maruani, G. Néliat, D. Caput, P. Ferrara, P. Soubrié, J. Breliere, G. Le Fur   +13 more
semanticscholar   +1 more source

Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Metabolic dysfunction‐associated fatty liver disease (MAFLD), recently redefined from non‐alcoholic fatty liver disease (NAFLD), highlights the central role of metabolic dysfunction in its pathophysiology. The L‐α‐lysophosphatidylinositol/G protein‐coupled receptor 55 (LPI/GPR55) axis, an element of the endocannabinoidome, has emerged as a key
Jerome Lian, Ricky R Lareu, Mohan Patil, Marco Falasca   +3 more
wiley   +1 more source

Melatonin mitigates hormonal toxicity in cannabis-treated female Wistar rats: involvement of cannabinoid receptor. [PDF]

J Cannabis Res
Oluwasola A.
europepmc   +1 more source

Exploring the Therapeutic Potential of Cannabidiol in Cutaneous Squamous Cell Carcinoma: An Integrated Computational and Experimental Study

International Journal of Quantum Chemistry, Volume 126, Issue 5, March 5, 2026.
Cannabidiol (CBD) exhibits increased reactivity, stronger CB1 receptor binding, and enhanced cytotoxicity against A431 squamous carcinoma cells compared to 5‐fluorouracil (5‐FU). Integrated DFT, molecular docking, and experimental analyses demonstrate CBD's improved stability and binding affinity, highlighting its potential as an alternative ...
Andrea Jess Josiah, Krishna Kuben Govender, Penny Poomani Govender, Werner Cordier, Margo Nell, Suprakas Sinha Ray   +5 more
wiley   +1 more source

Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning. [PDF]

Cell Mol Life Sci
Oyagawa CRM, Woodhouse B, Wood KC, Glass M, Grimsey NL.   +4 more
europepmc   +1 more source

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

British Journal of Pharmacology, 2015
R. Laprairie, A. Bagher, M. Kelly, E. Denovan‐Wright   +3 more
semanticscholar   +1 more source